Press Releases
-
OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million
-
OnKure Announces the Appointment of Dylan Hartley, Ph.D. as Chief Scientific Officer
-
OnKure Announces the Appointment of Rogan Nunn, J.D., as General Counsel and Secretary
-
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
-
OnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical Officer
-
OnKure Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for its Mutant Selective PI3Kα inhibitor, OKI-219
-
OnKure Therapeutics Appoints Ann Howell, Pharm.D., as Vice President of Regulatory Affairs
-
OnKure Therapeutics Announces $54 Million Series C Financing
-
OnKure Therapeutics Appoints Robbie Alton, Pharm., as Vice President of Clinical Operations
-
OnKure Therapeutics Appoints Kevin S. Litwiler, Ph.D., as Senior Vice President of DMPK and Clinical Pharmacology
-
OnKure Therapeutics Announces First Patient Dosed in the Phase 1b/2 Nautilus Trial of OKI-179 in Combination with Binimetinib in Patients with Advanced NRAS-Mutated Melanoma
-
OnKure Therapeutics Expands Boulder Footprint with the Opening of a New Research Laboratory
-
OnKure Therapeutics Announces Promising Preclinical Data on OKI-179 in RAS-Mutated Tumor Models Presented in a Late-Breaking Session at AACR
-
OnKure Therapeutics to Present Late-Breaking Preclinical Data on OKI-179 at the AACR Annual Meeting 2022
-
OnKure Therapeutics Appoints Jason Leverone, CPA, as Chief Financial Officer
-
OnKure Therapeutics Appoints Nicholas A. Saccomano, Ph.D., to its Board of Directors
-
OnKure Therapeutics Announces Positive Topline First-in-Human Phase 1 Results for OKI-179
-
OnKure Therapeutics Appoints Mark L. Boys, Ph.D., as Vice President of Discovery Chemistry
-
OnKure Therapeutics Appoints Jennifer R. Diamond, M.D., as Chief Medical Officer
-
OnKure Expands Executive Team with the Addition of Chief Scientific Officer and Chief Development Officer
-
OnKure Builds its Discovery Team and Appoints Heads of Computational Drug Discovery and Pharmacology
-
OnKure, Inc. Raises $55 Million Series B Financing
-
OnKure and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Combination of OKI-179 and Binimetinib
-
OnKure Expands Executive Team and Appoints Head of Discovery, Chief Financial Officer and General Counsel
-
OnKure and CU Cancer Center announce first patient enrolled in clinical trial of OKI-179, a potent and selective HDAC inhibitor
-
OnKure Announces FDA IND Regulatory Clearance to Start Phase 1 Trials for OKI-179
-
OnKure Close $7M Series A Financing to Support Development of Epigenetics Drug